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Supervised drug consumption facilities, where illicit drugs 
can be used under the supervision of trained staff, have been 
operating in Europe for the last three decades. These facilities 
primarily aim to reduce the acute risks of disease transmission 
through unhygienic injecting, prevent drug-related overdose 
deaths and connect high-risk drug users with addiction 
treatment and other health and social services. They also seek 
to contribute to a reduction in drug use in public places and 
the presence of discarded needles and other related public 
order problems linked with open drug scenes. Typically, drug 
consumption rooms provide drug users with: sterile injecting 
equipment; counselling services before, during and after 
drug consumption; emergency care in the event of overdose; 
and primary medical care and referral to appropriate social 
healthcare and addiction treatment services.
With the emergence and rapid spread of human 
immunodeficiency virus/acquired immune deficiency 
syndrome (HIV/AIDS) linked to epidemics of heroin use and 
drug injecting in the 1980s, a range of responses geared 
towards reducing the harms associated with drug injection 
and other high-risk forms of use were developed in Europe. 
These included services such as outreach, peer education, 
health promotion, the provision of clean injecting equipment 
and opioid substitution treatment. While harm reduction as 
a policy started to gain wider acceptance and expanded in 
Europe throughout the 1990s, one of the more controversial 
responses has been to make spaces available at local drugs 
facilities where drug users could consume drugs under 
supervision. Concerns have sometimes been expressed 
that consumption facilities might encourage drug use, delay 
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treatment entry or aggravate the problems of local drug 
markets, and initiatives to establish drug consumption rooms 
have in some cases been prevented by political intervention 
(Jauffret-Roustide et al., 2013). Nevertheless, as the debate 
about opening new drug consumption rooms remains high 
on the political agenda in a number of European countries, 
this analysis aims to provide an objective overview of their 
characteristics and current provision, and of the effectiveness 
of this intervention.
Drug consumption rooms are professionally supervised 
healthcare facilities where drug users can consume drugs 
in safer conditions. They seek to attract hard-to-reach 
populations of users, especially marginalised groups and 
those who use on the streets or in other risky and unhygienic 
conditions. One of their primary goals is to reduce morbidity 
and mortality by providing a safe environment for more 
hygienic use and by training clients in safer use. At the same 
time, they seek to reduce drug use in public and improve 
public amenity in areas surrounding urban drug markets. A 
further aim is to promote access to social, health and drug 
treatment facilities (see ‘Service model’).
Drug consumption rooms initially evolved as a response to 
health and public order problems linked to open drug scenes 
and drug markets in cities where a network of drug services 
already existed, but where difficulties were encountered 
in responding to these problems. As such they represent a 
‘local’ response, closely linked to policy choices made by 
local stakeholders, based on an evaluation of local need and 
determined by municipal or regional options to proceed. 
Facilities for supervised drug consumption tend to be located 
in settings that are experiencing problems of public use and 
targeted at sub-populations of users with limited opportunities 
for hygienic injection (e.g. people who are homeless or living 
in insecure accommodation or shelters). In some cases clients 
who are more socially stable also use drug consumption 
rooms for a variety of reasons, for example because they live 
with non-using partners or families (Hedrich and Hartnoll, 
2015).
In terms of the historical development of this intervention, the 
first supervised drug consumption room was opened in Berne, 
Switzerland in June 1986. Further facilities of this type were 
established in subsequent years in Germany, the Netherlands, 
Spain, Norway, Luxembourg, Denmark, Greece and France. 
A total of 78 official drug consumption facilities currently 
operate in seven EMCDDA reporting countries, following the 
opening of the first two drug consumption facilities in the 
framework of a 6-year trial in France in 2016. There are also 12 
facilities in Switzerland (see ‘Facts and figures’). 
I  Facts and figures 
Map with location and number of drug consumption room 
facilities throughout Europe:
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Breaking this down further, as of February 2017 there are: 
31 facilities in 25 cities in the Netherlands; 24 in 15 cities 
in Germany; five in four cities in Denmark 13 in seven cities 
in Spain; two in two cities in Norway; two in two cities in 
France; and one in Luxembourg (Luxembourg is preparing 
to open a second facility in 2018); and 12 in eight cities in 
Switzerland. In Slovenia following a change in the penal code 
that created an enabling environment for the opening of 
supervised consumption facilities, a planned pilot project is 
pending. Following HIV outbreaks among people who inject 
drugs, discussions about the introduction of supervised drug 
consumption facilities are ongoing in Glasgow (Scotland) 
and Dublin (Ireland). A study to explore the feasibility of drug 
consumption facilities in five major cities in Belgium (Ghent, 
Antwerp, Brussels, Liège and Charleroi) was launched in 
2016. Outside Europe there are two facilities in Vancouver 
(Canada) and one medically supervised injecting centre in 
Sydney (Australia).
I  Characteristics
A number of features are common to the majority of drug 
consumption facilities, irrespective of where they are located. 
For example, access is typically restricted to registered service 
users, and certain conditions, for example minimum age and 
local residency, have to be met. They usually operate from 
separate areas attached to existing facilities for drug users 
or homeless people, while some are stand-alone units. Most 
target drug injectors, though they increasingly include users 
who smoke or inhale drugs. 
Overall, three models of drug consumption rooms are 
operational in Europe: integrated, specialised and mobile 
facilities. The vast majority of drug consumption rooms 
are integrated in low-threshold facilities. Here, supervision 
of drug consumption is one of several survival-oriented 
services offered at the same premises, including provision 
of food, showers and clothing to those who live on the 
streets, prevention materials including condoms and sharps 
containers, and counselling and drug treatment. Specialised 
consumption rooms only offer the narrower range of services 
directly related to supervised consumption, which includes 
the provision of hygienic injecting materials, advice on health 
and safer drug use, intervention in case of emergencies and 
a space where drug users can remain under observation 
after drug consumption. Mobile facilities currently exist in 
Barcelona and Berlin; these provide a geographically flexible 
deployment of the service, but typically cater for a more 
limited number of clients than fixed premises (Schäffer et al., 
2014).
A recently published organisational overview of 62 drug 
consumption facilities in seven European countries (Woods, 
2014) shows that they deliver a wide range of auxiliary 
services. In addition to providing clean injecting equipment 
and health education advice, and referring clients to treatment 
and further care, 60–70 % of facilities offer access to primary 
healthcare by a nurse or physician (see Figure 1).
Figure 1: Service range at drug consumption facilities
Source: Based on Table 6.1 in Woods, 2014.
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A survey of 33 consumption room managers (1) (Woods, 2014) 
showed that, on average, their facilities offer seven places for 
supervised injection (ranging between one and 13 slots) and 
four places for smoking/inhaling. Over half of the facilities 
provide the service on a daily basis, opening on average for 
eight hours a day. The number of daily visitors varied widely — 
between 20 and 400 — with six of the 33 facilities catering for 
more than 200 clients a day. Addiction treatment facilities and 
the police were identified as the main sources of referral.
I  Evidence of effectiveness
The first drug consumption rooms were set up in Swiss, 
German and Dutch cities in response to health and public 
order concerns linked to open drug scenes. Although set 
up and supported by a range of local stakeholders, the 
facilities were experimental in the beginning and sometimes 
controversial. Subsequently, local service providers, public 
health authorities and the police carefully monitored the 
situation before and after the opening of the facilities and 
documented whether intended changes were achieved. 
Service model for a supervised drug consumption facility  
Assessment and 
intake
Supervised 
consumption area
Other service areas Referral
To determine eligibility for 
using the service, control of 
o
cial access criteria
To provide information on 
consumption room 
functioning/house rules
To provide information 
about risk avoidance/safer 
use
To provide hygienic 
equipment
To obtain information on 
drugs to be used
To determine individual 
needs (e.g. assess health 
status)
To ensure lower-risk, more 
hygienic drug consumption
To supervise consumption 
and ensure compliance 
with house rules (e.g. no 
drug sharing, dealing)
To provide tailor-made 
safer use advice
To provide emergency care 
in case of overdoses and 
other adverse reactions
To provide a space for drug 
use that is protected from 
public view
To prevent loitering in the 
vicinity of the room (police 
cooperation)
To monitor the eects of 
drug consumption among 
clients who have left the 
consumption area
To provide primary medical 
care services: abscess and 
wound clinic
To provide drinks, food, 
clothes, showers
To provide crisis interven-
tions
To provide a needle and 
syringe programme/safe 
needle disposal devices
To provide further services 
at the same facility, e.g. 
shelter, case management, 
counselling, treatment
To provide information 
about treatment options
To motivate clients to seek 
further treatment
To refer clients to further 
services, e.g. detoxication, 
substitution treatment, 
accommodation, social 
welfare, medical care
To establish contact 
with hard-to-reach 
populations
To identify and refer 
clients needing 
medical care
To reduce immediate risks related to drug consumption
To reduce morbidity and mortality
To stabilise and promote clients’ health
To reduce public nuisance
To increase client 
awareness of treatment 
options and promote 
clients’ service access
To increase chances 
that client will accept a 
referral to treatment
Survival
Increased social integration
Outcome 
objectives
Main 
compo-
nents
Imple-
mentation 
objectives
(1) Facilities in the Netherlands not included.
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Outcomes were reported directly to local and sometimes 
national policymakers, but data were rarely published in 
the international literature. The results remained relatively 
inaccessible to the international research community until 
reviews in the English language were published (Kimber et 
al., 2003; EMCDDA, 2004). However, supervised injecting 
facilities established in Sydney and Vancouver as pilot 
projects, accompanied by well-funded university-based 
evaluation studies using elaborate designs (including cohort 
study) resulted in a substantial body of evidence (for an 
overview see www.sydneymsic.com and supervisedinjection.
vch.ca). 
The effectiveness of drug consumption facilities to reach and 
stay in contact with highly marginalised target populations has 
been widely documented (Hedrich et al., 2010; Potier et al., 
2014). This contact has resulted in immediate improvements 
in hygiene and safer use for clients (e.g. Small et al., 2008, 
2009; Lloyd-Smith et al., 2009), as well as wider health and 
public order benefits.
Research has also shown that the use of supervised drug 
consumption facilities is associated with self-reported 
reductions in injecting risk behaviour such as syringe 
sharing. This reduces behaviours that increase the risk of 
HIV transmission and overdose death (e.g. Stoltz et al., 2007; 
Milloy and Wood, 2009). Nevertheless, the impact of drug 
consumption rooms on the reduction of HIV or hepatitis C 
virus incidence among the wider population of injecting drug 
users remains unclear and hard to estimate (Hedrich et al., 
2010; Kimber et al., 2010), due in part to the facilities’ limited 
coverage of the target population and also to methodological 
problems with isolating their effect from other interventions.
Some evidence has been provided by ecological studies 
suggesting that, where coverage is adequate, drug 
consumption rooms may contribute to reducing drug-related 
deaths at city level (Poschadel et al., 2003; Marshall et al., 
2011). A study in Sydney showed that there were fewer 
emergency service call-outs related to overdoses at the times 
the safe injecting site was open (Salmon et al., 2010).
In addition, the use of consumption facilities is associated 
with increased uptake both of detoxification and drug 
dependence treatment, including opioid substitution. For 
example, the Canadian cohort study documented that 
attendance at the Vancouver facility was associated with 
increased rates of referral to addiction care centres and 
increased rates of uptake of detoxification treatment and 
methadone maintenance (Wood et al., 2007; DeBeck et al., 
2011).
Evaluation studies have found an overall positive impact on 
the communities where these facilities are located. However, 
as with needle and syringe programmes, consultation 
with local key actors is essential to minimise community 
resistance or counter-productive police responses. Drug 
treatment centres offering supervised consumption facilities 
have generally been accepted by local communities and 
businesses (Thein et al., 2005). Their establishment has been 
associated with a decrease in public injecting (e.g. Salmon et 
al., 2007) and a reduction in the number of syringes discarded 
in the vicinity (Wood et al., 2004). For example, in Barcelona, 
a fourfold reduction was reported in the number of unsafely 
disposed syringes being collected in the vicinity from a 
monthly average of over 13 000 in 2004 to around 3 000 in 
2012 (Vecino et al., 2013).
The effect of the Sydney supervised injecting facility on drug-
related property crime and violent crime in its local area was 
examined using time series analysis of police-recorded theft 
and robbery incidents (Freeman et al., 2005). No evidence 
was found that the existence of the facility led to either an 
increase or decrease in thefts or robberies around the facility. 
Similarly, a study by Wood and colleagues compared the 
monthly number of charges for drug trafficking, assaults and 
robbery — crimes that are commonly linked to drug use — in 
Vancouver’s Downtown Eastside the year before versus the 
year after the local drug consumption room opened and found 
that the establishment of the facility was not associated with a 
marked increase in these crimes (Wood et al., 2006). 
In areas reporting an increase in the use of inhalable drugs, 
such as crack cocaine smoking, drug consumption facilities 
that originally targeted only injectors have started to broaden 
their services to include supervised inhalation. Findings 
suggest that supervised inhalation facilities offer the potential 
to reduce street disorder and encounters with the police 
(DeBeck et al., 2011). This change in service provision is 
taking place in a context where there is a decrease in the 
prevalence of heroin injecting and an increase in access to 
opioid substitution treatment. In this context some facilities 
Video on drug consumption rooms available on the EMCDDA website:  
www.emcdda.europa.eu/topics/pods/drug-consumption-rooms
I  Interactive element: video
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have adapted service provision to the needs of inner city 
crack-using populations.
In summary, the benefits of providing supervised drug 
consumption facilities may include improvements in safe, 
hygienic drug use, especially among regular clients, increased 
access to health and social services, and reduced public drug 
use and associated nuisance. There is no evidence to suggest 
that the availability of safer injecting facilities increases drug 
use or frequency of injecting. These services facilitate rather 
than delay treatment entry and do not result in higher rates of 
local drug-related crime.
I  Conclusion
Drug consumption facilities have the ability to reach and 
maintain contact with high-risk drug users who are not 
ready or willing to quit drug use. In a number of European 
countries supervised consumption has become an integrated 
component of low-threshold services offered within drug 
treatment systems. In Switzerland and Spain some drug 
consumption rooms have been closed, primarily due to the 
reduction in injecting heroin use and a decline in the need for 
such services, but also sometimes due to cost considerations. 
In Greece the operation of the facility was suspended after 
the first nine months due to delays in establishing a legal 
basis, and the service provider is working with the Ministry of 
Health to prepare its re-opening. In the Netherlands cutbacks 
were made following a reduction in the number of visitors, 
linked to the success of another programme (Plan van Aanpak 
Maatschappelijke Opvang) that brought homeless people into 
(supervised) accommodation where the use of drugs is often 
allowed. Alcohol consumption rooms, which tend to be located 
in the same building but in separate rooms, are increasingly 
combined with drug consumption facilities in the Netherlands 
(Netherlands Reitox Focal Point, 2016).
The emergence of new forms of stimulant injection, 
including new psychoactive substances, has resulted in 
potentially increased risks for drug users. In this context, 
drug consumption rooms are currently the subject of political 
discussion in some European countries as calls for their 
implementation are debated. As frontline, low-threshold 
services, drug consumption rooms are often among the first 
to gain insights into new drug use patterns and thus they 
also have a role to play in the early identification of new and 
emerging trends among the high-risk populations using their 
services.
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